AI Article Synopsis
- The study focuses on the need for new prognostic markers and treatment targets in the diverse landscape of breast cancer, using the METABRIC dataset to analyze gene expression.
- It found that higher levels of PD-L1 and MET genes are linked to poorer tumor characteristics and are more prevalent in certain aggressive breast cancer subtypes.
- The research suggests that targeting both PD-L1 and MET may be beneficial, especially for patients with tumors showing high levels of these proteins, even though their expression did not directly correlate with overall survival rates.
Article Abstract
Introduction: The heterogeneity of breast cancer requires exploring novel prognostic biomarkers as well as therapeutic targets for the treatment of the disease.
Methods: The METABRIC dataset was used to describe the gene expression of the programmed death-ligand 1 (PD-L1) and the hepatocyte growth factor receptor (MET) and their association with the tumor clinicopathologic characteristics and overall survival in breast cancer.
Results: The expression of the PD-L1 and MET genes correlated positively with the Nottingham Prognostic Index (NPI) (p=0.003 and p < 0.001, respectively). The expression of the two genes correlated inversely with luminal A and luminal B tumors (r= - 0.089, p= 0.021 and r= - 0.116, p= 0.013, respectively). The PD-L1 mRNA levels were significantly higher in hormone receptor-negative and HER2-positive tumors. MET mRNA expression levels were significantly higher in hormone receptor-negative, HER2-enriched, and non-luminal breast cancers. The PD-L1/MET double-high expression was associated with younger age of patients at diagnosis, higher NPI scores, larger tumors, advanced stage, high-grade, hormone receptor-negativity, HER2-positivity, and non-luminal tumors. None of the genes or their double expression status was significantly associated with overall survival in this analysis.
Conclusion: The expression of the PD-L1 and MET genes is remarkably associated with worse tumor clinicopathologic features and poor prognosis in patients with breast cancer. Further investigations using combination drug regimens targeting PD-L1 and MET are important, particularly in breast tumors expressing high levels of both proteins.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/0115680096333231240902070108 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy.
Eur Urol
December 2024
Department of Oncology, University of Debrecen, Debrecen, Hungary.
Article Synopsis
- - Patients with advanced/metastatic urothelial carcinoma who previously responded to or maintained stable disease with pembrolizumab immunotherapy may benefit from retreatment after disease progression, based on a post hoc analysis involving 49 patients from earlier clinical trials.
- - The study found that 41% of these patients achieved an objective response following retreatment, with a notable percentage having had a complete response during the initial treatment, and the median duration of the response was around 14 months.
- - Additionally, the retreatment led to manageable adverse effects, with only 45% experiencing treatment-related events, indicating that pembrolizumab retreatment is a viable and relatively safe option for select patients.
Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma.
Future Oncol
December 2024
Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Background: The co-occurrence of PD-L1 positivity and EGFR mutations in advanced NSCLC often limits EGFR-TKIs effectiveness, with unclear mechanisms.
Methods: We analyzed 103 treatment-naive EGFR-mutant LUAD patients from three centers, assessing PD-L1 expression and performing NGS analysis.
Results: SMO mutations and MET amplification were significantly higher in the PD-L1 ≥ 1% group versus PD-L1 < 1% group (SMO: 8% vs.
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.
Oncoimmunology
December 2025
Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, Japan.
This retrospective, multicenter cohort study aimed to determine whether cancer cachexia serves as a biomarker for determining the most effective treatment for patients having non-small-cell lung cancer (NSCLC) with high programmed death ligand 1 (PD-L1) expression treated with immune checkpoint inhibitors (ICIs) alone or combined with chemotherapy (ICI/chemotherapy). We included 411 patients with advanced NSCLC with a PD-L1 tumor proportion score of ≥50%. The patients were treated with pembrolizumab monotherapy or ICI/chemotherapy.
View Article and Find Full Text PDFc-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity.
Front Immunol
December 2024
Department of Biochemistry, Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland.
Article Synopsis
- - c-MET, or hepatocyte growth factor receptor (HGFR), is a key protein linked to various types of solid tumors and is associated with poorer treatment outcomes due to its connection to therapeutic resistance and expression alongside PD-L1.
- - Tumor cells and myeloid-derived suppressor cells (MDSCs) activate c-MET signaling through hepatocyte growth factor (HGF), which disrupts immune function by depleting crucial amino acids, ultimately creating an immunosuppressive tumor environment.
- - The review discusses potential c-MET-targeted immunotherapies, such as CAR therapies and monoclonal antibodies, highlighting their promise in improving cancer treatment and the importance of understanding the underlying molecular mechanisms for developing effective
Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1.
Front Oncol
November 2024
Labcorp Oncology, Durham, NC, United States.
Introduction: Matching patients to an effective targeted therapy or immunotherapy is a challenge for advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one marker at a time. Unlike traditional single marker tests, comprehensive genomic profiling (CGP) can simultaneously assess NSCLC tumors for hundreds of genomic biomarkers and markers for immunotherapy response, leading to quicker and more precise matches to therapeutics.
Methods: In this study, we performed CGP on 7,606 patients with advanced or metastatic NSCLC using the Illumina TruSight Oncology 500 (TSO 500) CGP assay to show its coverage and utility in detecting known and novel features of NSCLC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!